Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.38 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376484 | 1.00 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL30486896 | 1.00 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL29302070 | 0.90 | MAP2K1 (0.45) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL29302051 | 0.90 | PTK2 (0.38) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL26047143 | 0.90 | KDM4E (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL29302065 | 0.89 | MAP2K1 (0.44) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL21979501 | 0.87 | MAP2K1 (0.45) | MAP2K1 | |
| SCHEMBL30486879 | 0.87 | MAP2K1 (0.45) | MAP2K1 | |
| SCHEMBL21979482 | 0.86 | MAP2K1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL21979513 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3624796-B1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-111065393-A | Pyrrolopyridine-anilines for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2020-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, PRKDC, MAPK1 | MAP2K1 224/4885MAP2K2 220/4885MAP2K5 168/4885 |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | ADH1C, SIK1, PKN2 | MAP2K1 550/4885MAP2K2 425/4885MAP2K5 318/4885 |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885MAP2K5 297/4885 |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885MAP2K5 297/4885 |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 434/4885MAP2K2 265/4885MAP2K5 280/4885 |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885MAP2K5 297/4885 |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NCOA3, TYR, CYP3A43 | MAP2K1 2772/4885MAP2K2 2465/4885MAP2K5 2466/4885 |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MAP2K1 435/4885MAP2K2 263/4885MAP2K5 274/4885 |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885MAP2K5 297/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MAP2K1 3307/4885MAP2K2 3471/4885MAP2K5 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.